Weekly Digest – October 2024 Weekly Digest – October 2024 10 Oct 2024: Ono enters into license agreement for LCB97, an Antibody-Drug Conjugate, and research collaboration and license agreement to generate novel ADC candidates by leveraging ConjuAll ADC platform with […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: MediLink Therapeutics and Amgen announce global clinical collaboration to evaluate combination therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) MediLink Therapeutics has partnered with Amgen to explore […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study Adcendo’s ADC candidate, ADCE-D01, received IND clearance from the US FDA and will enter […]
Weekly Digest – October 2024 Weekly Digest – October 2024 8 Oct 2024: CSPC Pharmaceutical announces CPO301 receives Fast Track Designation (FTD) from US FDA CSPC Pharmaceutical Group’s CPO301, a first-in-class ADC, received Fast Track Designation from the US FDA […]
Weekly Digest – October 2024 Weekly Digest – October 2024 10 Oct 2024: AstraZeneca’s dual-antibody ADC approved for two clinical trials in China AstraZeneca’s innovative drug AZD9592 has received implicit licensing for two clinical trials in China, targeting advanced solid […]
